UNICEF launches Central African Republic disease drive
This article was originally published in Scrip
Executive Summary
UNICEF has launched a malaria, measles and diarrhoea campaign targeting 800,000 children in the Central African Republic (CAR). The 10-day initiative will provide 885 vaccination sites and enrol 1,750 health workers, providing measles vaccines for children under five, free soap to help prevent diarrhoea, and treated mosquito nets to fight malaria. A goal of reaching 80% of children in the CAR has been set by the charity. UNICEF has also begun a multimedia campaign to advertise the initiative, including posters, radio spots and news articles.
You may also be interested in...
How to leverage India: Five up-and-coming domestic players
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
Active Biotech appoints CSO
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed appoints new chief commercial officer
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).